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Systemic Reduction in Glutathione Levels Occurs in
Patients with Primary Open-Angle Glaucoma
Doina Gherghel,1,2 Helen Rosemary Griffiths,1 Emma Jane Hilton,1,2 Ian Andrew Cunliffe,2
and Sarah Louise Hosking1,2
PURPOSE. To assess the level of plasma glutathione in patients
with untreated primary open-angle glaucoma.
METHODS. Twenty-one patients with newly diagnosed primary
open-angle glaucoma and 34 age- and gender-matched control
subjects were subjected to a blood analysis to detect the level
of circulating glutathione in its reduced and oxidized forms.
The effect of age, gender, and systemic blood pressure on
circulating glutathione levels was also analyzed.
RESULTS. Age had a negative effect on the level of both reduced
and total glutathione (P 0.002, r0.52 and P 0.002, r
0.52, respectively) in control subjects but not in patients
with glaucoma (P  0.05, r  0.27, and P  0.05, r  0.22,
respectively). In the control group, men demonstrated higher
levels of both reduced and total glutathione than did women
(P  0.024 and P  0.032, respectively). After correction for
age and gender influences on blood glutathione levels, patients
with glaucoma exhibited significantly lower levels of reduced
and total glutathione than did control subjects (P  0.010, F 
7.24 and P  0.006, F  8.38, respectively). No differences
between study groups were observed in either oxidized gluta-
thione levels or redox index (P 0.05, F 0.50; and P 0.05,
F  0.30, respectively).
CONCLUSIONS. Patients with glaucoma exhibit low levels of cir-
culating glutathione, suggesting a general compromise of the
antioxidative defense. (Invest Ophthalmol Vis Sci. 2005;46:
877–883) DOI:10.1167/iovs.04-0777
Primary open-angle glaucoma (POAG) is a chronic, slowlyprogressive optic neuropathy, characterized by excavation
of the optic nerve head (ONH) and a distinctive pattern of
visual field (VF) defects.1 The disease is multifactorial in origin
and is associated more closely with elevated intraocular pres-
sure (IOP) resulting in the main from reduced drainage of
aqueous humor. Nevertheless, approximately one third of pa-
tients with glaucoma exhibit apparently normal IOP. More-
over, a substantial number of POAG cases continue to progress
despite therapeutically lowered IOP. All these observations
have spurred further research to determine the existence of
other possible risk factors for glaucoma.2
Besides more extensively investigated factors, such as in-
creased IOP,3,4 reduced ocular blood flow (OBF),5–9 ocular
vascular dysregulation,10–16 and systemic blood pressure (BP)
alterations,17–21 oxidative stress has also been proposed as a
contributing factor in the etiology of glaucomatous optic neu-
ropathy.22–26 Oxidative stress represents a harmful state de-
fined by the presence of pathologic levels of reactive oxygen
species (ROS) relative to antioxidant defense. ROS are mole-
cules that oxidize more strongly than oxygen (O2) itself, or
molecules containing oxygen that generate free radicals. ROS
include superoxide (O2
), hydrogen peroxide (H2O2) and hy-
droxyl radical (OH), which is the strongest oxidant produced
in biological systems. Other reactive species, reactive nitrogen
species (RNS), include nitric oxide and peroxynitrite (ONOO),
a product resulting from the reaction between ROS and nitric
oxide (NO).
In certain situations, free radicals can be generated in an
exaggerated manner and can injure tissues and organs by
interacting with lipids, proteins, or DNA.27 Oxidative stress has
been implicated in a large number of human diseases, includ-
ing different autoimmune diseases,28 alcoholic liver disease,29
cancer,30 and infection with human immunodeficiency virus
(HIV)31 and in ischemia-reperfusion injury.32
To survive, the human body has developed a complex,
efficient, and highly adaptive antioxidant defense system that
includes two categories of antioxidants: (1) enzymatic, such as
glutathione peroxidase (GPx), glutathione reductase (GSSGR),
superoxide dismutase (SOD), catalase (CAT), and peroxire-
doxin,33 and (2) nonenzymatic, such as reduced glutathione
(GSH), antioxidant vitamins, and low-molecular-weight com-
pounds such as urate.34
The eye is also protected against oxidative stress by several
mechanisms involving antioxidant enzymes such as CAT and
SOD, as well as by low-molecular-weight antioxidants such as
GSH and ascorbate.35 Glutathione (GSH, L--glutamyl-L-cystei-
nylglycine), a tripeptide consisting of glycine, cysteine, and
glutamic acid, prevents the effects of ROS either directly as an
antioxidant or indirectly, by maintaining other cellular antioxi-
dants in a functional state.36,37 GSH conjugates with a large
variety of products of oxidative stress and carcinogens via
reactions facilitated by the enzyme glutathione S-transferase
(GST). In living organisms, glutathione exists in two forms:
reduced (GSH) and oxidized (GSSG). An optimal GSH: GSSG
ratio is critical for survival of the cells and tight regulation of
the system is therefore very important.38
Abnormal levels of GSH have already been reported in the
lens39–41 and whole blood42 of patients with age-related cata-
ract, in the vitreous humor, in the blood of patients with
proliferative diabetic retinopathy (PDR) or proliferative vitreo-
retinopathy (PVR),43 and in the blood of patients with age-
related macular degeneration (ARMD).44,45 Altered GSH and
GSH activity has also been reported in the trabecular mesh-
work and aqueous humor of patients with glaucoma.23–26 In a
recent study, Yang et al.46 demonstrated the presence of serum
antibodies against GST in patients with glaucoma. The results
of these studies are of extreme importance. A deficit in the
scavenging capacity of GSH could reduce the bioavailability of
NO for vasodilation, with consequent disruption of vascular
From the 1School of Life and Health Sciences, Aston University,
Birmingham, United Kingdom; and the 2Department of Ophthalmol-
ogy, Heartlands and Solihull NHS Trust, Birmingham, United Kingdom.
Submitted for publication July 1, 2004; revised October 7, 2004;
accepted November 10, 2004.
Disclosure: D. Gherghel, None; H.R. Griffiths, None; E.J.
Hilton, None; I.A. Cunliffe, None; S.L. Hosking, None
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked “advertise-
ment” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Helen Griffiths, School of Life and Health
Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK;
h.r.griffiths@aston.ac.uk.
Investigative Ophthalmology & Visual Science, March 2005, Vol. 46, No. 3
Copyright © Association for Research in Vision and Ophthalmology 877
Downloaded from iovs.arvojournals.org on 02/12/2019
tone. Although a deficit in NO could result in altered ocular
perfusion pressure (OPP) in glaucoma,47 to date no study has
been undertaken to investigate whether altered systemic GSH
levels occur in patients who have this disease. Consequently, it
is important to determine whether there is a relationship be-
tween circulating levels of GSH and the occurrence of POAG.
The purpose of the present study was to establish circulating
GSH and GSSG levels in patients with newly diagnosed and
previously untreated POAG.
SUBJECTS AND METHODS
Study Sample
Consecutive patients with newly diagnosed and previously untreated
POAG attending the Fast Track Glaucoma Clinic at the Heartlands and
Solihull NHS Trust (Birmingham, UK) between February 2002 and
December 2003, were considered for inclusion in this prospective
study. Ethical approval was obtained from the local medical ethics
committee, and written informed consent was received from all sub-
jects before entry into the study. The study was designed and con-
ducted in accordance with the tenets of Declaration of Helsinki.
Patients underwent diurnal IOP phasing and were diagnosed as
having POAG if IOP measurements were greater than 21 mm Hg by
applanation tonometry (with at least two of the measurements being
higher than 24 mm Hg), glaucomatous cupping of the optic disc on
fundoscopic examination, normal open anterior chamber angles by
gonioscopy, and repeatable VF defects consistent with the diagnosis of
glaucoma, according to results obtained with program 24-2 of the
Humphrey Field Analyzer (HFA: Carl Zeiss Meditec, Dublin, CA). The
study’s ocular exclusion criteria included narrow iridocorneal angles,
evidence of secondary open-angle glaucoma, history of previous in-
traocular surgery, and other nonglaucomatous ocular diseases includ-
ing cataract, diabetic retinopathy (DR) and ARMD. Forty-six patients
with previously untreated glaucoma were screened during the study
period. However, only 33 patients met these first criteria.
The control group was recruited from patients’ spouses and from
other volunteers, and it was composed of subjects who had never
neither glaucoma nor other ocular diseases such as cataract, DR, or
ARMD.
Other exclusion criteria for both groups were smoking and a
history of any chronic systemic disease with presumed low GSH levels,
including autoimmune diseases,28 alcoholic liver disease,29 cancer,30
and diabetes mellitus.48 After this selection, the experimental group
was narrowed to 21 patients with glaucoma and 34 control subjects.
BP Measurement
BP was measured in each patient and control subject in the morning
between 8 and 9 AM, with a BP monitor (UA-779; A&D Instruments,
Ltd., Oxford, UK). In preparation for this measurement, each subject
rested in a sitting position for approximately 10 minutes in a quiet
room to achieve sufficient mental and physical calm. The systolic BP
(SBP) and diastolic BP (DBP) were measured three times (1 minute
apart). The average readings for SBP and DBP were then used to
calculate the mean BP (MBP) using the formula: MBP 2⁄3DBP 1⁄3SBP.
Blood Sampling
Subjects were instructed to fast between 9 PM and retiring on the
evenings before the blood drawing. On the morning of the test,
subjects were requested to have only a light breakfast, such as simple
toast. They were asked to avoid any cooked breakfast, meat, cereal,
fresh fruits, fruit juice, and any nutritional supplements.49 Subjects
were also asked to abstain from caffeinated beverages and chocolate
and from alcohol for at least 2 hours before the visit.
All blood samples were obtained by a qualified phlebotomist in the
morning, between 9 and 10 AM. Seven milliliters of blood was col-
lected in EDTA-treated tubes (to prevent oxidation50) by venipuncture
to the antecubital vein. Thirty microliters of blood was then transferred
into centrifuge tubes for initial processing. The GSH was released from
the blood cells by protein precipitation and cellular disruption
achieved by addition of 33.3 L of 5-sulfosalicylic acid (SSA), 100
mg/mL within 10 minutes from the blood collection.51 Each sample
was then diluted with 936.7 L sodium phosphate buffer (pH 7.5), and
the content of each tube was mixed rapidly in a centrifuge at 13,000
rpm for 5 minutes. A portion of supernatant (150 L) was then
collected into clean centrifuge tubes and immediately cooled at
70°C. Samples stored at this temperature are stable for at least 2
months and can be transported on dry ice without deterioration.52
FIGURE 1. The standard curve for the GSH assay.
FIGURE 2. The standard curve for the GSSG assay.
TABLE 1. Reagents and Equipment Used for the GSH Assay
Reagents
Sodium phosphate buffer: 125 mM containing 6.3 mM disodium
EDTA (pH 7.5)
Daily buffer: 3 mg NADPH into 10 mL sodium phosphate buffer
DTNB solution: 47.56 mg 5.5 DTNB into 20 mL sodium phosphate
buffer
SSA solution: 1 g SSA in 1 mL distilled water
GSH solution: 15.35 mg GSH in 0.5 mL distilled water
Enzyme: 41.6 L GSSGR in 5.158 mL sodium phosphate buffer
Equipment
Pipettes: 1000 L, 100 L, 2 L
Adjustable multichannel pipettes: 5–50 L, 50–250 L
Flat-bottomed 96-well assay plate
96-Well plate reader
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Blood Analysis
GSH Assay. The total GSH levels (t-GSH) were assessed by the
GSSGR-DTNB (5.5 dithiobis-2-nitrobenzoic acid) recycling procedure,
as described in previous studies.50,53 The reagents and equipment used
for this assay are listed in Table 1.
A standard curve from 0 to 2 nanomoles in 0.5-nanomole incre-
ments using GSH solution (0.2–0.8 L) was prepared. The standards
contained the same final concentrations of SSA as for the samples (1%).
To each well of a 96-well plate, 150 L of daily buffer (see Table 1), 50
L of DTNB solution, and 25 L of standards or samples were added in
quadruplicate, and the plate was incubated at 37°C for 3 minutes.
Finally, 25 L GSSGR was added to the previous mixture, and the plate
was read at 410 nm using a 96-well plate reader.54 A standard curve
was then generated by linear regression (Excel; Microsoft, Redmond,
WA; Fig. 1).
GSSG Assay. The GSSG levels were assessed with a DTNB-GSSGR
recycling assay.50 The reagents used in this assay were those described
in Table 1 and, in addition, triethanolamine (TEA) and 2-vinyl pyridine
(2-VP). TEA prevents a high local pH and oxidation, whereas 2-VP is
used to stabilize GSH.
A GSSG standard curve from 0 to 0.25 nanomole, in 0.025-nano-
mole increments was prepared. Standards and samples (100 L) were
transferred into separate centrifuge tubes and 2 L 2-VP was added to
each tube. TEA was then used to adjust the pH of the standards/
samples to 7.5.
To each well of the 96-well plate, 150 L of daily buffer, 50 L of
DTNB solution, and 25 L of standards or samples were added in
quadruplicate, and the plate was incubated at 37°C for 3 minutes.
Finally, 25 L of GSSGR was added to the previous mixture, and the
plate was read at 410 nm with a 96-well plate reader. A standard curve
was then generated by linear regression (Excel Microsoft; Fig. 2).
Finally, the GSH levels (GSH t-GSH GSSG) and the redox index
(defined as the GSH to GSSG ratio) were calculated.
Statistical Analysis
The statistical analysis was performed on computer (Statistica for
Windows; StatSoft, Tulsa, OK). Data are expressed as the mean  SD.
Differences between groups at baseline for age, gender, and systemic
BP parameters were calculated using Student’s t-test for unpaired
variables. A multivariate analysis was performed to test the influence of
age, gender, and systemic BP on blood GSH levels. Differences be-
tween the two study groups in blood GSH levels were computed by
analysis of covariance (ANCOVA). P 0.05 was considered statistically
significant.
RESULTS
Twenty-one patients with POAG (7 men and 14 women) and
34 control subjects (15 men and 19 women) years were in-
cluded in the study. The characteristics of the study groups are
given in Table 2. There was no significant difference in age and
systemic BP between patients with glaucoma and control sub-
jects (P 0.05); however, there were significant differences in
IOP (P  0.001), and the measured VF parameters (mean
deviation [MD]P  0.020 and pattern standard deviation
[PSD]P  0.001, respectively).
The Effect of Age and SBP
In the control group, age had a negative effect on the level of
both GSH (P 0.002, r0.52; Fig. 3) and t-GSH (P 0.002,
r  0.52; Fig. 4) but not on the level of GSSG and redox
index (P  0.05, r  0.17; and P  0.05, r  0.25,
respectively). In patients with glaucoma, however, blood GSH
FIGURE 3. The influence of age on plasma GSH levels.
TABLE 2. Characteristics of the Study Groups
Parameter
Glaucoma Patients
(n  21)
Control Subjects
(n  34) P
Age (y) 72.40  11.00 68.45  10.11 0.05
IOP (mm Hg) 24.04  5.47 18.68  3.59 0.001
MD (dB) 5.03  7.47 1.05  2.00 0.020
PSD (dB) 5.74  3.62 1.70  0.42 0.001
SBP (mm Hg) 142.72  20.95 142.24  23.66 0.05
DBP (mm Hg) 79.99  12.34 82.76  12.36 0.05
MBP (mm Hg) 100.90  13.58 102.58  15.24 0.05
FIGURE 4. The influence of age on t-GSH levels.
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levels were not significantly influenced by age (GSH: P  0.05,
r  0.27; t-GSH: P  0.05, r  0.22; GSSG: P  0.05, r 
0.27; and redox index: P  0.05, r  0.25). There was no
significant association between blood GSH levels and systemic
BP in either of the study groups (P  0.05).
Gender Effect
There were no differences in the proportion of men and
women included in the study groups (P  0.05, 2 test). The
relationship between gender and blood GSH levels is illustrated
in Table 3. In the control group, men demonstrated higher
levels of both GSH (P  0.024; Fig. 5) and t-GSH (P  0.032;
Fig. 6). GSSG and redox index levels were similar in both men
and women (P  0.05). In the glaucoma group, men and
women had similar levels of blood GSH (P  0.05).
Intergroup Differences in Blood GSH
Table 4 shows blood GSH and GSSG levels in both study
groups. After correcting for age and gender influence on blood
GSH levels, patients with glaucoma exhibited significantly
lower levels of GSH and t-GSH than control subjects (P 
0.010, F  7.24; and P  0.006, F  8.38, respectively; Figs. 7
8). There were no significant differences between study
groups in GSSG levels and redox index (P  0.05, F  0.50;
and P  0.05, F  0.33, respectively).
DISCUSSION
The present study assessed the circulating GSH and GSSG
levels in patients with newly diagnosed and previously un-
treated POAG. Our results disclosed that, independent of age
and gender, patients with glaucoma demonstrated lower GSH
and t-GSH levels than age-matched control subjects. GSSG
levels and redox index, however, were similar in both study
groups.
GSH is among the most efficient substances that cells and
tissues use in their defense against oxidative stress.37 Age and
disease, however, act to decrease the amount of GSH available
in the organism. It has been demonstrated that at least half of
apparently healthy elderly individuals show low blood GSH
levels.55–57 Indeed, our results show a negative correlation
between age and both GSH and t-GSH levels in control sub-
jects. This effect was lost in the glaucoma group. In the general
population, age is strongly associated with increased oxidative
stress and reduced antioxidant status.58 The loss of this corre-
lation between age and GSH loss in patients with POAG dem-
onstrated in the present study could indicate that a more
important, independent factor than age influences GSH levels
in this cohort.
It has been shown that blood GSH levels are influenced by
gender, with men demonstrating higher levels than women.59
Our results also show that in control subjects, men had higher
levels of GSH and t-GSH than did women. Nevertheless, in
patients in the glaucoma group both genders demonstrated
similar blood GSH levels, which again suggests an overriding
modulation of GSH in POAG that exceeds that afforded by
either gender or age.
Clinical and laboratory studies performed so far have dem-
onstrated a significant decrease in blood GSH concentration in
both patients and animals with various systemic28–31 and ocu-
lar 42–45 diseases. Although recent studies have shown that
there are altered levels of GSH and GSH activity in the trabec-
ular meshwork and aqueous humor of patients with glau-
coma,23–26 to date no study has demonstrated an abnormal
GSH level in the blood of patients with POAG.
FIGURE 5. Men demonstrated higher levels of GSH than did women in
the control group, but not the POAG group.
FIGURE 6. Men demonstrated higher levels of t-GSH than did women
in the control group but not in the POAG group.
TABLE 3. Gender Influence on Blood GSH Levels
Parameter
Glaucoma Patients (n  21) Control Subjects (n  34)
Men
(n  7)
Women
(n  14) P
Men
(n  15)
Women
(n  19) P
GSH (nmol) 225.42  111.50 224.85  87.36 0.05 338.47  120.32 265.62  50.68 0.024
GSSG (nmol) 34.13  8.94 25.22  20.80 0.05 36.10  16.98 34.94  18.09 0.05
Redox index (GSH/GSSG) 10.29  7.13 9.13  6.27 0.05 10.90  5.24 10.24  7.72 0.05
t-GSH (nmol) 249.93  96.45 258.98  80.44 0.05 372.35  126.16 300.55  54.85 0.032
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Circulating GSH can be depleted either by subjecting cells
to oxidative stress, or by inhibition of synthesis. In patients
with glaucoma, due to a high level of oxidative stress,22–26 GSH
could be overused in reactions that result in GSSG produc-
tion.51 Nevertheless, our study groups demonstrated similar
GSSG levels. One explanation could be that the GSSG resulted
from the reaction between GSH, and ROS is rapidly reduced
back to GSH, thus completing the normal redox cycle.60 In
normal conditions, GSSG is quite effective in maintaining GSH
in its reduced state.60 Our patients with glaucoma, however,
demonstrated a significantly lower GSH level than control sub-
jects, indicating that this mechanism played a role in our model
and implying that the protection against ROS afforded by GSH
could be reduced in patients with this disease, possibly due to
a defective redox cycle.
Another possible reason for low GSH levels in our patients
with glaucoma could be defective intracellular synthesis. The
liver is the major site for GSH synthesis.61 The precursors
necessary for this synthesis are L-glutamate, L-cysteine, and
L-glycine and the first step of the reaction, catalyzed by GSC, is
controlled by a negative feedback from its end product, GSH.62
In the present study, however, the level of GSH in patients
with glaucoma was found to be low, therefore suggesting that
the limiting factors in this case could be the availability of
precursors of GSH.60 Although both glutamate and glycine are
important, it seems that the major determinant of the rate of
GSH synthesis is the availability of the amino acid cysteine
(Cys).63 Cysteine results from the metabolism of homocysteine
(Hcy) in the presence of cofactors such as vitamins B6, B12,
and folate. Any interruption in the Hcy-Cys pathway could
result, not only in the accumulation of the former but also in
less available quantities from the second amino acid. In high
concentrations, Hcy has been implicated in the etiology of
various cardio- and cerebrovascular diseases.64–66 Because
vascular risk factors are implicated in the etiology of
POAG,5–9,12–21 one could hypothesize that abnormal levels of
circulating Hcy are to be found in patients with this disease.
The results of recent research published on this subject have
been contradictory. Bleich et al.67 reported higher plasma Hcy
levels in patients with POAG than in control subjects whereas,
in a more recent study, Wang et al.69 did not detect any
significant difference in plasma Hcy between patients with
POAG and control subjects. In the present study, we did not
seek to quantify the plasma Hcy in our patients and control
subjects. We suggest that the abnormal low level of GSH in
patients with glaucoma could be at least partially explained by
a lower availability of Cys due to an abnormal Hcy-Cys meta-
bolic pathway.
A low level of circulating GSH may also result in a higher
rate of oxidative reactions that reduce the bioavailability of
NO. Several studies have shown that NO is also involved in the
regulation of systemic hemodynamics,69,70 with disturbed NO
homeostasis contributing to alterations in systemic vascular
diseases such as hypertension or diabetes, in which basal
formation of NO is impaired.71,72 It has also been hypothesized
that a low NO production has a major effect on the equilibrium
between the endothelial vasoconstrictive and vasodilatory fac-
tors at the ocular level that could also result in a decreased OBF
in susceptible patients with glaucoma.73 In addition to the
hemodynamic role, NO has also been shown to induce relax-
ation of the trabecular meshwork and the ciliary muscle, re-
sulting in a decrease in IOP.74 Any disturbance in the NO
balance could therefore act both at the ocular and systemic
levels47 and have dramatic consequences on the progression of
glaucoma. It can been suggested that in some patients with
glaucoma, not only the high level of IOP but also the occur-
rence of vasospasm75 and thrombosis76 can be the result of
reduced NO bioavailability due to low levels of circulating
GSH.
In conclusion, our study demonstrated for the first time that
untreated patients with POAG exhibit low levels of circulating
FIGURE 7. Patients with glaucoma exhibited lower levels of GSH than
did control subjects.
FIGURE 8. Patients with glaucoma exhibited lower levels of t-GSH
than did control subjects.
TABLE 4. Blood Glutathione Levels in the Study Groups
Parameter
Glaucoma Patients
(n  21)
Control Subjects
(n  34) P
GSH (nmol) 225.27  83.03 332.23  98.50 0.010
GSSG (nmol) 31.79  18.61 35.34  17.64 0.05
Redox index (GSH/GSSG) 9.44  6.34 10.52  6.69 0.05
t-GSH (nmol) 256.28  83.03 333.04  99.92 0.006
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GSH, suggesting a general compromise to antioxidative de-
fense. Further investigations are needed, to identify the cause
of this biochemical deficiency.
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